Full Breakdown
Trump’s Omitted Hair-Loss Drug Raises Health-Transparency Concerns
6/4/2026, 11:10:04 PM
Core Event
A medical summary released after President Donald Trump’s latest Walter Reed exam omitted finasteride, the hair-loss drug he has taken for years, marking the first absence of the medication from a publicly disclosed list since his inauguration.
Background
Finasteride (Propecia) is an oral 5-alpha-reductase inhibitor used to prevent male-pattern baldness and to lower prostate-specific antigen (PSA) levels. Three physicians who treated Trump before and during his first term confirmed his use of the drug.
Data
Since returning to office, Trump’s PSA rose tenfold, from 0.1 ng/mL to 1.0 ng/mL; Dr. Jonathan Reiner noted the rise. Finasteride normally lowers PSA, so the rise aligns with its removal. He has completed at least three Walter Reed visits in the past 13 months, including a heart-abdomen MRI with no abnormalities. The report said he is in excellent physical health and fully fit for office. An Ipsos poll found 59 % doubted his mental acuity and 55 % questioned his physical health.
Official Response
The White House said the report reflects all relevant medications and that no undisclosed health conditions were omitted. Trump’s physician, Dr. Sean Barbabella, concluded he remains in excellent physical health. Spokesperson Davis Ingle called Trump the sharpest, most accessible, energetic president in history and dismissed medical commentary as arm-chair diagnosis. Trump said the MRI was not of his brain because he “aced” a cognitive test.
Opposition
Columbia University psychiatrist Robert Klitzman warned the omission “raises significant questions of what else is possibly not being revealed,” noting finasteride’s link to depression. Dr. Jonathan Reiner highlighted “severe daytime somnolence” and chronic insomnia, risks for dementia. Dr. John Gartner said repeated testing “suggests medical professionals may be monitoring dementia, rather than just screening for it.” Critics say the missing data obscures the PSA rise.
Gaps
The White House says it is not obligated to disclose the medication regimen, leaving it unclear whether Trump stopped finasteride or continues it. The PSA increase is documented, but no prostate disease diagnosis has been provided. The report does not explain the drug’s removal.
Quotes
“The current report reflects all medications deemed clinically relevant to disclose at this time.” — White House spokesperson
“No additional undisclosed conditions or procedures materially affecting his health status were omitted from this report.” — White House statement
“It raises significant questions of what else is possibly not being revealed.” — Robert Klitzman, Columbia University psychiatrist
“He falls asleep very often. He’s fallen asleep in the Oval Office on multiple occasions with people talking to him, in the cabinet room…And chronic insomnia is a severe illness.” — Dr. Jonathan Reiner, CNN medical analyst
